Cargando…
Novel anticancer agents : strategies for discovery and clinical testing /
This book offers pertinent basic science information on strategies used for the rational design and discovery of novel anticancer agents, and, in addition, translational studies involving clinical trial design and execution with these novel, mostly cytostatic agents. This book covers basic science s...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam ; London :
Academic,
�2006.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn162570263 | ||
| 003 | OCoLC | ||
| 005 | 20231117014923.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 070806s2006 ne a ob 001 0 eng d | ||
| 040 | |a OPELS |b eng |e pn |c OPELS |d DEBSZ |d OCLCQ |d N$T |d YDXCP |d OCLCE |d IDEBK |d OCLCQ |d BDX |d OCLCQ |d E7B |d OCLCQ |d CASUM |d OCLCA |d OCLCF |d D6H |d OCLCO |d OCLCA |d LEAUB |d OL$ |d LVT |d OCLCO |d OCLCQ |d OCLCO |d COM |d OCLCQ |d OCL |d OCLCQ |d OCLCO | ||
| 019 | |a 173240308 |a 173807080 |a 607662736 |a 648324467 |a 657966791 |a 974757820 |a 974852736 |a 989403823 |a 1011245455 |a 1024249702 |a 1027486809 |a 1086423012 |a 1119419745 |a 1160054477 |a 1229528980 |a 1229765290 | ||
| 020 | |a 9780120885619 | ||
| 020 | |a 0120885611 | ||
| 020 | |a 9780080537757 |q (electronic bk.) | ||
| 020 | |a 0080537758 |q (electronic bk.) | ||
| 035 | |a (OCoLC)162570263 |z (OCoLC)173240308 |z (OCoLC)173807080 |z (OCoLC)607662736 |z (OCoLC)648324467 |z (OCoLC)657966791 |z (OCoLC)974757820 |z (OCoLC)974852736 |z (OCoLC)989403823 |z (OCoLC)1011245455 |z (OCoLC)1024249702 |z (OCoLC)1027486809 |z (OCoLC)1086423012 |z (OCoLC)1119419745 |z (OCoLC)1160054477 |z (OCoLC)1229528980 |z (OCoLC)1229765290 | ||
| 042 | |a dlr | ||
| 050 | 4 | |a RS431.A64 |b N68 2006eb | |
| 060 | 4 | |a 2006 B-357 | |
| 060 | 4 | |a QV 269 |b N9367 2006 | |
| 072 | 7 | |a MED |x 062000 |2 bisacsh | |
| 072 | 7 | |a HEA |x 039030 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.994061 |2 22 |
| 084 | |a VS 9100 |2 rvk | ||
| 245 | 0 | 0 | |a Novel anticancer agents : |b strategies for discovery and clinical testing / |c editors Alex A. Adjei, John K. Buolamwini. |
| 260 | |a Amsterdam ; |a London : |b Academic, |c �2006. | ||
| 300 | |a 1 online resource (xv, 437 pages, [20] pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a This book offers pertinent basic science information on strategies used for the rational design and discovery of novel anticancer agents, and, in addition, translational studies involving clinical trial design and execution with these novel, mostly cytostatic agents. This book covers basic science strategies that are being used in drug discovery and preclinical evaluation focused on novel molecular targets, as well as clinical trial methodology including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new, relatively non-cytotoxic anticancer agents. At present, there is no book that provides such an integration of basic and clinical studies of novel anticancer agents, covering both drug discovery and translational research extensively. * Addresses the critical issues involved in the development of novel agents for cancer therapy by experts in the field * Presents drug discovery strategies * Discusses regulatory issues surrounding drug development *. | ||
| 505 | 0 | |a Section A: Strategies for Drug Discovery. -- 1. A Survey of Novel Molecular Targets for Anticancer Drug Discovery. -- 2. Microarrays: Small Spots Produce Major Advances in Pharmacogenomics. -- 3. Strategies to Target Chemotherapeutics to Tumors. -- 4. QSAR and Pharmacophore Mapping Strategies in Novel Anticancer Drug Discovery. -- 5. Applications of Nuclear Magnetic Resonance and Mass Spectrometry to Anticancer Drug Discovery. -- 6. Antisense Strategies for the Development of Novel Cancer Therapeutics. -- 7. Antibodies and Vaccines as Novel Cancer Therapeutics. -- 8. Inhibitors of Apoptosis (IAPs) as Targets for Cancer Therapy. -- 9. Preclinical Testing and Validation of Novel Anticancer Agents. -- Section B: Methods for Clinical Testing of Novel Agents. -- 10. Biologic Endpoints and Surrogate Markers for Ealry Trials of Novel Anticancer Agents. -- 11. Regulatory Considerations in Clinical Trials of Novel Anticancer Drugs. -- 12. Improving the Efficacy and Safety of Anticancer Agents -- The Role of Pharmacogenetics. -- 13. Imaging of Pharmacodynamic Endpoints in Clinical Trials. -- 14. Devising Proof of Concept Strategies in Oncology Clinical Trials. -- 15. Clinical Trial Designs for Cytostatic Agents and Agents Directed at Novel Molecular Targets. -- 16 Cancer Gene Therapy Clinical Trials: From the Bench to the Clinic. -- 17. Molecular Targest for Radiosensitization. -- 18. Patient Accrual to Clinical Trials. | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a A survey of novel molecular targets for anticancer drug discovery -- Microarrays: small spots produce major advances in pharmacogenomics -- Strategies to target chemotherapeutics to tumors -- QSAR and pharmacophore mapping strategies in novel anticancer drug discovery -- Applications of nuclear magnetic resonance and mass spectrometry to anticancer drug discovery -- Antisense strategies for the development of novel cancer therapeutics -- Antibodies and vaccines as novel cancer therapeutics -- Inhibitors as targets for cancer therapy -- Preclinical testing and validation of novel anticancer agents -- Surrogate end points and biomarkers for early trials of novel anticancer agents -- Regulatory considerations in clinical trials of novel anticancer drugs -- Improving the efficacy and safety of anticancer agents: the role of pharmacogenetics -- Imaging of pharmacodynamic end points in clinical trials -- Devising proof-of-concept strategies in oncology clinical trials -- Clinical trial designs for cytostatic agents and agents directed at novel molecular targets -- Cancer gene therapy clinical trials: from the bench to the clinic -- Molecular targets for radiosensitization -- Patient accrual to clinical trials. | |
| 588 | 0 | |a Print version record. | |
| 506 | |3 Use copy |f Restrictions unspecified |2 star |5 MiAaHDL | ||
| 533 | |a Electronic reproduction. |b [Place of publication not identified] : |c HathiTrust Digital Library, |d 2010. |5 MiAaHDL | ||
| 538 | |a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. |u http://purl.oclc.org/DLF/benchrepro0212 |5 MiAaHDL | ||
| 583 | 1 | |a digitized |c 2010 |h HathiTrust Digital Library |l committed to preserve |2 pda |5 MiAaHDL | |
| 650 | 0 | |a Antineoplastic agents |x Development. | |
| 650 | 0 | |a Antineoplastic agents |x Research |x Methodology. | |
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 1 | 2 | |a Antineoplastic Agents |x pharmacokinetics |0 (DNLM)D000970Q000493 |
| 650 | 2 | 2 | |a Drug Delivery Systems |0 (DNLM)D016503 |
| 650 | 2 | 2 | |a Drug Design |0 (DNLM)D015195 |
| 650 | 6 | |a Anticanc�ereux |0 (CaQQLa)201-0004692 |x D�eveloppement. |0 (CaQQLa)201-0375083 | |
| 650 | 6 | |a Anticanc�ereux |0 (CaQQLa)201-0004692 |x Essais. |0 (CaQQLa)201-0375087 | |
| 650 | 6 | |a Anticanc�ereux |0 (CaQQLa)201-0004692 |x Recherche |0 (CaQQLa)201-0380850 |x M�ethodologie. |0 (CaQQLa)201-0380850 | |
| 650 | 6 | |a M�edicaments |x Conception. |0 (CaQQLa)201-0203461 | |
| 650 | 7 | |a MEDICAL |x Oncology. |2 bisacsh | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x Cancer. |2 bisacsh | |
| 650 | 7 | |a Drugs |x Design |2 fast |0 (OCoLC)fst00898790 | |
| 650 | 7 | |a Antineoplastic agents |x Development |2 fast |0 (OCoLC)fst00810599 | |
| 700 | 1 | |a Adjei, Alex A. | |
| 700 | 1 | |a Buolamwini, John K. | |
| 776 | 0 | 8 | |i Print version: |t Novel anticancer agents. |d Amsterdam ; London : Academic, �2006 |z 0120885611 |z 9780120885619 |w (DLC) 2006272967 |w (OCoLC)64899077 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780120885619 |z Texto completo |